Tech · NZ ·

ASP-1929 + Pembrolizumab Shows 28-Month Median OS in HNSCC Study

The Clinical Trial Vanguard · Tech

Published

ASP-1929 + Pembrolizumab Shows 28-Month Median OS in HNSCC Study

Read it at the source

The Clinical Trial Vanguard↗

We link out rather than republish. The reporting belongs to the publications above; the summary and the search data on this page are ours.

More trending now